Emory University
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
To determine the optimal schedule for three-dimensional verification imaging and necessary re-planning of patients undergoing IMPT for a rapidly changing tumor (small cell lung cancer). * To determine the rate of cardiac toxicities from IMPT in patients with small cell lung cancer compared with historical controls receiving photon-based treatment. * To determine the rate of pneumonitis and esophagitis from IMPT and compare with historical controls receiving photon based treatment.
Inclusion Criteria: * Pathologically confirmed small cell lung cancer, limited or extensive stage. * Patients who are offered thoracic radiotherapy with intensity-modulated proton therapy (IMPT) techniques delivering 30-66 Gy in 15-33 fractions at 2 Gy per fraction, at the recommendation of the treating radiation oncologist. * Age 18 or greater Exclusion Criteria: * Prior radiation therapy which would provide significant dose overlap with the planned target volume(s) * Pregnancy
The goal of intensity-modulated proton therapy (IMPT) is to deliver radiation to the tumor while minimizing exposure to surrounding normal tissues.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.